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Abstract
Context: Mitochondrial ATP production is important in the regulation of glucose-stimulated insulin
secretion. Genetic factors may modulate the capacity of the b-cells to secrete insulin and thereby
contribute to the risk of type 2 diabetes.
Objective: The aim of this study was to identify genetic loci in or adjacent to nuclear-encoded genes of
the oxidative phosphorylation (OXPHOS) pathway that are associated with insulin secretion in vivo.
Design and methods: To ﬁnd polymorphisms associated with glucose-stimulated insulin secretion, data
from a genome-wide association study (GWAS) of 1467 non-diabetic individuals, including the
Diabetes Genetic Initiative (DGI), was examined. A total of 413 single nucleotide polymorphisms with
a minor allele frequency R0.05 located in or adjacent to 76 OXPHOS genes were included in the DGI
GWAS. A more extensive population-based studyof 4323 non-diabetics, the PPP-Botnia, was used as a
replication cohort. Insulinogenic index during an oral glucose tolerance test was used as a surrogate
marker of glucose-stimulated insulin secretion. Multivariate linear regression analyses were used to
test genotype–phenotype associations.
Results: Two common variants were identiﬁed in the DGI, where the major C-allele of rs606164,
adjacent to NADH dehydrogenase (ubiquinone) 1 subunit C2 (NDUFC2), and the minor G-allele of
rs1323070, adjacent to cytochrome c oxidase subunit VIIa polypeptide 2 (COX7A2), showed nominal
associations with decreased glucose-stimulated insulin secretion (PZ0.0009, respective PZ0.003).
These associations were replicated in PPP-Botnia (PZ0.002 and PZ0.05).
Conclusion: Our study shows that genetic variation near genes involved in OXPHOS may inﬂuence
glucose-stimulated insulin secretion in vivo.
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Introduction
Type 2 diabetes is a heterogeneous disease where
multiple genes and environmental factors combine to
cause the disease. Genetic factors may directly affect the
risk of type 2 diabetes by modulating the capacity of the
b-cells to secrete insulin and/or by inducing insulin
resistance in target tissues. Mitochondrial dysfunction
has been suggested to contribute to both impaired
insulin secretion and insulin resistance (1, 2).I n
pancreatic b-cells, mitochondria play a key role in
regulating insulin secretion. Oxidative phosphorylation
(OXPHOS) by the respiratory chain, which contains ﬁve
enzyme complexes embedded in the mitochondrial
inner membrane, is coupled to conversion of ADP into
ATP. Elevated plasma glucose levels will cause a rise in
the b-cell ATP/ADP ratio, which is a main trigger for
insulin secretion (3). Mitochondrial dysfunction could
thereby lead to impaired insulin secretion from the
b-cells and subsequently to an increased risk of type 2
diabetes. The multi-protein complexes in the OXPHOS
system contain w90 protein subunits encoded by both
the nuclear and mitochondrial genomes (4), where the
mitochondrial genome encodes 13 of the subunits
present. A previous study from our group has shown
the mRNA expression of peroxisome proliferator-
activated receptor gamma coactivator 1 alpha
(PPARGC1A), a master regulator of mitochondrial
genes, to be reduced in islets from patients with type 2
diabetes and this reduction correlates with impaired
glucose-stimulated insulin secretion (5). In addition, a
common polymorphism (rs8192678) inﬂuences
PPARGC1A mRNA expression and insulin secretion in
the human islets. Even though a mutation in mito-
chondrial DNA has been found in a rare but speciﬁc
form of diabetes (maternally inherited diabetes and
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DNA has not been associated with metabolic diseases
(6, 7). Mitochondrial genes encoded by the nuclear
genome have been implicated in the pathogenesis
of diabetes (8, 9). However, only a small number of
studies have reported whether polymorphisms in
nuclear-encoded genes involved in OXPHOS inﬂuence
the risk of the disease (5, 10–12), e.g. a polymorphism
in NDUFB6 (rs540467) has been associated with
increased risk of type 2 diabetes (12).
Recent genome-wide association studies (GWASs),
including the Diabetes Genetic Initiative (DGI), have
provided new insights into the nature of the genetic
factors involved in the pathogenesis of type 2 diabetes
(13). Since mitochondrial ATP production is important
in the regulation of glucose-stimulated insulin
secretion, we examined if polymorphisms in or near
nuclear-encoded genes of the respiratory chain are




The DGI is a case–control-based study, where patients
with type 2 diabetes, geographically matched controls
and discordant sibships were selected from Finland
and Sweden (13). Patients with type 2 diabetes were
classiﬁed according to WHO (1999) criteria with
fasting plasma glucose R7.0 mmol/l or a 2 h glucose
R11.1 mmol/l during an oral glucose tolerance test
(OGTT) and 1464 patients were included in the DGI.
Non-diabetic subjects were deﬁned as normal glucose
tolerant, with fasting plasma glucose !6.1 mmol/l and
2 h glucose !7.8 mmol/l. Population-based non-dia-
betic subjects had no ﬁrst-degree relatives with type 2
diabetes and included 1467 individuals (Table 1)
(13). Only non-diabetic subjects were included in the
current study.
Prevalence, Prediction and Prevention of diabetes
(PPP-Botnia) is a population-based study in the Botnia
region of Western Finland (14). The participants were
aged 18–75 years (mean age 48.4G15.6 years).
Diagnosis of type 2 diabetes was conﬁrmed from subject
records or on the basis of fasting plasma glucose
concentration R7.0 mmol/l and/or 2 h glucose
R11.1 mmol/l. Only non-diabetic subjects (nZ4323)
were included in the current study, where 612 (14%)
had fasting plasma glucose levels between 6.1 and
6.9 mmol/l (Table 1).
All participants gave written informed consent for the
studies and the local ethics committees approved the
protocols.
Assays and measurements
Blood samples for measurements of plasma glucose and
serum insulin concentrations were drawn at 0, 30 and
120 min of the 75 g OGTT in both DGI and PPP-Botnia.
Plasma glucose was measured in DGI with a glucose
oxidase method (Beckman Glucose Analyzer, Beckman
Instruments, Fullerton, CA, USA) and in PPP-Botnia
with a glucose dehydrogenase method (HemoCue,
A ¨ ngelholm, Sweden). Three different methods for
measurement of insulin concentrations were used in
both DGI and PPP-Botnia: RIA (Pharmacia), enzyme
linked immunoassay (DAKO Diagnostics Ltd, Cambrid-
geshire, UK) and ﬂuoroimmunoassay (Delphia, Perkin-
Elmer Finland, Turku, Finland). The Pharmacia and
Delphia values were transformed into ‘Dako’ values
using validated correction coefﬁcients.
b-cell function and glucose-stimulated insulin
secretion were assessed as insulinogenic index during
an OGTT ((insulin at 30 minKinsulin at 0 min)/(glu-
cose at 30 minKglucose at 0 min)) (15). Insulin
resistance estimated by the homeostasis model assess-
ment (HOMA-IR) was calculated as ((glucose at
0 min!insulin at 0 min)/22.5). b-Cell function was
also assessed in PPP-Botnia as disposition index, insulin
secretion adjusted for insulin resistance (insulinogenic
index/HOMA-IR).
Identiﬁcation of single nucleotide polymorph-
isms in the DGI GWAS
We aimed at identifying single nucleotide polymorph-
isms (SNPs) situated in a region 25 kb upstream and
25 kb downstream of nuclear-encoded OXPHOS genes
with a minor allele frequency (MAF) R0.05, showing
nominal associations (P%0.01) with insulinogenic
index in non-diabetic subjects in the DGI GWAS (13).
Identiﬁed polymorphisms were ranked based on the P
values of genotype–phenotype association. The Gene-
Chip Human Mapping 500K Array Set (Affymetrix,
Inc., Santa Clara, CA, USA) used in the DGI GWAS has
coverage in the CEU HapMap population (r
2%0.8) of
67%, based on single marker test. In the DGI GWAS,
Table 1 Clinical characteristics of non-diabetic participants in the
DGI and the PPP-Botnia. Data are expressed as meanGS.D.o r
median (IQR). Insulinogenic index: calculated as ((insulin at
30 minKinsulin at 0 min)/(glucose at 30 minKglucose at 0 min)).
HOMA-IR: calculated as ((glucose at 0 min!insulin at 0 min)/22.5).
Characteristics DGI PPP-Botnia
n (male/female) 1467 (707/760) 4323 (2043/2280)
Age (years) 58.8G10.1 47.6G15.2
BMI (kg/m
2) 26.6G3.7 26.3G4.3
Fasting glucose (mmol/l) 5.3G0.5 5.3G0.6
Glucose 30 min (mmol/l) 8.3G1.5 8.3G1.6
Glucose 120 min (mmol/l) 5.6G1.3 5.2G1.6
Fasting insulin (mU/l) 5.2 (4.3) 5.3 (4.2)
Insulin 30 min (mU/l) 50.2 (48.9) 50.4 (38.3)
Insulin 120 min (mU/l) 36.2 (29.7) 23.7 (26.2)
Insulinogenic index 14.1 (14.8) 15.9 (16.1)
HOMA-IR 1.46 (1.08) 1.26 (1.04)
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MAF criteria (Supplementary Table 1, see section on
supplementary data given at the end of this article) and
nine of these SNPs were also nominally associated with
insulinogenic index (P%0.01). The two top hits were
selected for follow-up in an independent cohort.
Genotyping
In the DGI GWAS, genotyping was performed using
Affymetrix 500K chip array (13). In PPP-Botnia,
rs606164 and rs1323070 were genotyped using allelic
discrimination assays on the ABI 7900 platform
(C__2983373_10 and C__3073719_10, Applied Bio-
systems, Foster City, CA, USA). The genotyping success
rates were O95.5% and the concordance rate was
100% based on 4.2% duplicate comparisons.
Statistical analyses
Linear regression analyses were performed to test
genotype–phenotype associations, assuming additive
genetic models in both DGI and PPP-Botnia. Phenotype
values were logarithmically transformed to ﬁt a normal
distribution in both cohorts before analyses.
In DGI, z-scores of insulinogenic index were prepared
separately by gender and recruiting region (Botnia,
Skara, Malmo ¨ or Helsinki) and regressed against
genotype adjusted for age, log body mass index (BMI)
and type of insulin measurement. Unrelated individuals
and siblings were included in this analysis. To correct
for inﬂation caused by inclusion of related individuals,
the genomic control inﬂation factor based on the
median test statistic was estimated, and P values
based on the test statistic adjusted by this factor are
reported (13).
In PPP-Botnia, the log-transformed phenotype values
were regressed against genotype adjusted for age, sex
and BMI.
All analyses were carried out in non-diabetic
individuals. Results are presented as median (inter-
quartile range) or b coefﬁcient (S.E.M.). Statistical
analyses were performed using SPSS version 17 for
Windows (SPSS, Chicago, IL, USA) or using STATA/SE
10.0 (STATA Corp. LP, College Station, TX, USA).
Results
Identiﬁcation of genetic loci associated with
insulin secretion
To ﬁnd genetic loci associated with insulin secretion in
or adjacent to nuclear-encoded genes of the respiratory
chain, we examined data from the DGI GWAS (13)
(Table 1). Nine SNPs representing six genes were
identiﬁed based on a MAFR0.05, nominal associations
to insulinogenic index with P%0.01 and they are
located in regions of 25 kb upstream or downstream of
OXHPOS genes (Table 2). Region plots of the six
identiﬁed OXPHOS genes are presented together with
Klog10 P values of all SNPs within these regions from
the DGI GWAS as well as Haploview presentations of the
LD-structure based on HapMap data (Supplementary
Figure 1A–F, see section on supplementarydata given at
the end of this article). Based on the lowest P values, two
SNPs were selected for follow-up: rs606164, 12 kb
upstream of NDUFC2, and rs1323070, 24 kb down-
stream of COX7A2. The major C-allele of rs606164 and
the minor G-allele of rs1323070 are nominally
associated with decreased glucose-stimulated insulin
secretion during an OGTT (insulinogenic index) in non-
diabetic subjects of DGI (rs606164: b K0.21G0.062,
PZ0.0009 and rs1323070: b K0.14G0.046,
PZ0.003). The common variant rs606164 was not
in LD with any of the other two SNPs identiﬁed in DGI
located adjacent to NDUFC2 (Table 2 and Supple-
mentary Figure 1A, see section on supplementary data
given at the end of this article). None of the variants
Table 2 SNPs identiﬁed from DGI GWAS located in a region of w25 kb upstream or downstream of OXHPOS genes with an association to
insulinogenic index in non-diabetic individuals of DGI with P%0.01 and MAFR0.05. In DGI P values are based on linear regression to test
association between genotype and insulinogenic index z-score with the covariates gender, recruiting region, age, BMI and type of insulin






(major/minor) MAF b (S.E.M.) P value
rs606164 11 w12 kb upstream NDUFC2 C/G 0.16 K0.21 (0.062) 9!10
K4
rs1323070 6 w24 kb downstream COX7A2 A/G 0.36 K0.14 (0.046) 3!10
K3
rs10793285 11 w20 kb upstream NDUFC2 T/G 0.36 K0.12 (0.044) 6!10
K3
rs1133322 15 w0.3 kb downstream COX5 A/G 0.49 K0.13 (0.045) 7!10
K3
rs2643338 8 Intron UQCRB A/G 0.47 K0.12 (0.045) 1!10
K2
rs7827095 8 w3 kb downstream UQCRB T/C 0.47 K0.12 (0.045) 1!10
K2
rs10734905 12 Intron ATP6OA2 G/T 0.32 K0.13 (0.049) 1!10
K2
rs1264913 1 w15 kb upstream ATP5F1 A/G 0.11 K0.18 (0.071) 1!10
K2
rs2845556 11 w20 kb upstream NDUFC2 C/T 0.49 K0.12 (0.46) 1!10
K2
MAF, minor-allele frequency.
aAllele denoted in bold associated with decreased insulinogenic index.
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control-based study of DGI GWAS or insulin resistance
(HOMA-IR) in non-diabetic subjects of DGI (13)
(Supplementary Table 1, see section on supplementary
data given at the end of this article).
Insulin secretion in vivo
We next investigated whether the NDUFC2 variant,
rs606164, and COX7A2 variant, rs1323070, were
associated with insulin secretion in a more extensive
replication cohort, the PPP-Botnia Study (14) (Table 1).
In line with the ﬁndings in DGI, C-allele carriers of
rs606164 showed decreased insulinogenic index in
the PPP-Botnia study (b K0.070G0.022, PZ0.002)
(Table 3). Moreover, G-allele carriers of rs1323070
showed a nominal association with insulinogenic index
in PPP-Botnia (b K0.040G0.021, PZ0.05) (Table 3).
Disposition index is an additional assessment of b-cell
function that considers the insulin resistance–secretion
relationship. When analysing disposition-index, C-allele
carriers of rs606164and G-allele carriers of rs1323070
also showed a decreased insulin secretion adjusted
for insulin resistance in PPP-Botnia (rs606164: b
K0.066G0.023, PZ0.007; rs1323070: b K0.040
G0.019, PZ0.03). Neither rs606164 nor rs1323070
was associated with HOMA-IR in PPP-Botnia (PZ0.79
and PZ0.57, respectively).
Discussion
In this study, we have demonstrated that two common
polymorphisms, rs606164 adjacent to NDUFC2 and
rs1323070 adjacent to COX7A2, are associated with
insulin secretion in vivo. Insulin secretion was measured
as insulinogenic index at 30 min, a well-known
measure of early-phase insulin secretion during an
OGTT (15, 16).
Mitochondrial ATP production by OXPHOS in the
respiratory chain is necessary for glucose-stimulated
insulin release by b-cells (17). Insulin secretion is
impaired in pancreatic islets from patients with type 2
diabetes partially due to impaired hyperpolarization of
the inner mitochondrial membrane and a failure to
respond with a rise in ATP levels (18), but the number of
identiﬁed polymorphisms in genes of the OXPHOS
process associated with type 2 diabetes and its risk
factors are limited.
Recent GWAS have focused on identifying genes
associated with type 2 diabetes and, today, more than
35 common variants have been identiﬁed that affect the
risk of the disease (13, 19–28). Although many of these
variants seem to affect the b-cell function and insulin
secretion (29, 30), only a few GWAS have included
measurements of glucose-stimulated insulin secretion
(31). Due to the importance of OXPHOS in the
regulation of insulin secretion, we examined if common
variants near nuclear-encoded genes of the respiratory
chain affect glucose-stimulated insulin secretion, using
data from a GWAS, the DGI. The identiﬁcation of
variants was based on one trait and for variantsin genes
of one speciﬁc molecular pathway. Among variants near
genes of the respiratory chain, rs606164 and
rs1323070 showed the strongest associations with
insulinogenic index in DGI. Although these associations
were not genome-wide signiﬁcant in the DGI, one
should keep in mind that the study was underpowered
for these associations, as they could only reliably be
assessed for non-diabetic individuals. We therefore used
a lower threshold for selection of SNPs for replication in
an independent study, PPP-Botnia. Our inclusion
criterium was to identify SNPs near nuclear-encoded
OXPHOS genes, which are associated with insulino-
genic index with P%0.01 and a MAFR0.05. Nine
variants fulﬁlled the criterium.
To conﬁrm the association of the two top hits, we
replicated the results in a more extensive population-
based cohort, the PPP-Botnia study from Western
Finland (14). In accordance with DGI, C-allele carriers
of rs606164 showed decreased insulin secretion and
there was a nominal association between rs1323070
and insulin secretion in PPP-Botnia. This effect was
maintained when adjusting for insulin resistance by
using disposition index. The inclusion of individuals
with impaired fasting glucose (IFG) in PPP-Botnia did
not affect our ﬁndings, since an association between
rs606164 and insulinogenic index as well as a trend
towards association for rs1323070 was observed even
when individuals with IFG were excluded.
The common variant rs606164 is located 12 kb
upstream of the NDUFC2 gene, a position where genetic
Table 3 Effects of rs606164 and rs1323070 on insulinogenic index in non-diabetic individuals of the PPP-Botnia study. Data are expressed
as median (IQR). b coefﬁciants (S.E.M.) are from linear regression analyses adjusted for age, sex and BMI based on an additive model.
Study SNP Phenotype
Genotypes
(genotype frequency) b S.E.M. P value
PPP-Botnia
(nZ4201)
rs606164 GG (0.024) CG (0.285) CC (0.691)
Insulinogenic
index
19.08 (14.54) 16.42 (15.92) 15.63 (16.13) K0.070 0.022 0.002
PPP-Botnia
(nZ4140)
rs1323070 AA (0.432) AG (0.441) GG (0.127)
Insulinogenic
index
16.17 (16.13) 15.90 (15.81) 15.25 (15.17) K0.040 0.021 0.05
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encodes NADH dehydrogenase (ubiquinone) 1 subunit
C2, which is located in complex I of the electron
transport chain. Complex I is the largest component of
the OXPHOS system and entry point of electrons from
NADH into the electron transport chain, thereby
playing a key role in regulating OXPHOS. NDUFC2
and its ﬂanking genes, thyroid hormone responsive
(THRSP) and asparagine-linked glycosylation 8 (ALG8),
appear to be conserved among chickens, humans, mice
and rats. Since rs606164 are in LD with SNPs located in
both THRSP and ALG8, we cannot exclude that the
effect on insulin secretion is mediated by these genes.
However, based on the function of these genes, they are
not likely to be involved in the regulation of insulin
secretion, and we therefore suggest that the found
association between rs606164 and insulinogenic index
is mediated via NDUFC2.
The position of rs1323070 is w24 kb downstream
of COX7A2. COX7A2 encodes cytochrome c oxidase
VIIa polypeptide 2, which is located in complex IVof the
electron transport chain. Complex IV catalyses the
electron transfers from cytochrome c to the reduction of
oxygen to water. Although the location of rs1323070 is
downstream of COX7A2 and not in LD with any SNP
within this OXPHOS gene, it mayaffect the expression of
COX7A2. It is also possible that rs1323070 inﬂuences a
gene upstream of the SNP or a so far unknown
regulatory region that mediates the effect on insulin
secretion. Taken together, common polymorphisms in
or near genes involved in OXPHOS may be of
importance in insulin secretion and/or the pathogenesis
of type 2 diabetes.
In conclusion, we have identiﬁed two polymorphisms
associated with glucose-stimulated insulin secretion
in vivo. These polymorphisms, rs606164 and
rs1323070, are located adjacent to nuclear-encoded
genes involved in OXPHOS. This is an exploratory
follow-up study of a published GWAS, DGI, where we
have selected SNPs nominal associated with insulin
secretion for replication in an independent study. It
remains to be shown whether the ﬁndings can be
replicated in even larger studies and inﬂuence the risk of
type 2 diabetes.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.
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